



---

**TTK Healthcare**  
**LIMITED**

---

TTKHC:SEC:GJ:229:22

October 31, 2022

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex  
Bandra East  
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Disclosure under Regulation 30 - Unaudited Financial Results along with Limited  
Review Report for the Second Quarter and Half-Year ended 30<sup>th</sup> September, 2022**

---

We take reference to the E-mail dated 29<sup>th</sup> October, 2022, from [query.lodr@bseindia.com](mailto:query.lodr@bseindia.com), regarding additional details required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015.

We also take reference to our Communication No.TTKH:SEC:GJ:227:22 dated 28<sup>th</sup> October, 2022, along with the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Second Quarter and Half-Year `ended 30<sup>th</sup> September, 2022.

As required, we are resubmitting the above referred communication with the details of the Board Meeting conclusion time.

Kindly take the above information on record.

Thanking you

Yours faithfully  
For TTK Healthcare Limited

**(S KALYANARAMAN)**  
*Wholetime Director & Secretary*

Encl. : a/a



---

**TTK Healthcare  
LIMITED**

---

TTKHC:SEC:GJ:227:22

October 28, 2022

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex  
Bandra East  
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Disclosure under Regulation 30 - Unaudited Financial Results along with Limited  
Review Report for the Second Quarter and Half-Year ended 30<sup>th</sup> September, 2022**

---

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Second Quarter and Half-Year ended 30<sup>th</sup> September, 2022, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on 27<sup>th</sup> October, 2022 and approved by the Board of Directors of the Company at their Meeting held today.

The Board Meeting commenced at 12 noon and concluded at 1.05 p.m.

Kindly take the above documents on record.

Thanking you

Yours faithfully  
For TTK Healthcare Limited

**(S KALYANARAMAN)**  
*Wholetime Director & Secretary*

Encl. : a/a

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2022****[Prepared in compliance with the Indian Accounting Standards (Ind AS)]****(Rs. in lakhs)**

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2022)	(30/06/2022)	(30/09/2021)	(30/09/2022)	(30/09/2021)	(31/03/2022)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	16,979.18	19,262.03	15,047.97	36,241.21	28,184.49	59,923.99
II.	Other Income	1,106.28	986.23	302.35	2,092.51	666.66	1,633.06
III.	<b>Total Income (I + II)</b>	<b>18,085.46</b>	<b>20,248.26</b>	<b>15,350.32</b>	<b>38,333.72</b>	<b>28,851.15</b>	<b>61,557.05</b>
IV.	Expenses:						
	(a) Cost of materials consumed	4,596.36	4,330.06	3,510.56	8,926.42	6,102.51	14,346.23
	(b) Purchase of Stock-in-trade	3,868.00	4,386.75	2,974.01	8,254.75	6,215.51	15,040.39
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(114.43)	552.41	342.04	437.98	91.09	(1,237.15)
	(d) Employee benefits expense	3,124.81	3,220.15	2,270.29	6,344.96	4,722.27	10,284.24
	(e) Finance Costs	79.61	270.91	37.43	350.52	82.99	323.75
	(f) Depreciation and Amortization Expense	332.08	319.75	311.25	651.83	630.35	1,258.36
	(g) Other Expenses	5,105.44	6,396.70	5,688.28	11,502.14	10,182.12	19,306.55
	<b>Total Expenses (IV)</b>	<b>16,991.87</b>	<b>19,476.73</b>	<b>15,133.86</b>	<b>36,468.60</b>	<b>28,026.84</b>	<b>59,322.37</b>
V.	<b>Profit / (Loss) before Exceptional Items and Tax (III - IV)</b>	<b>1,093.59</b>	<b>771.53</b>	<b>216.46</b>	<b>1,865.12</b>	<b>824.31</b>	<b>2,234.68</b>
VI.	Exceptional Items [Refer Note No.4 below]	-	-	249.05	-	249.05	249.05
VII.	<b>Profit / (Loss) before Tax (V - VI)</b>	<b>1,093.59</b>	<b>771.53</b>	<b>465.51</b>	<b>1,865.12</b>	<b>1,073.36</b>	<b>2,483.73</b>
VIII.	Tax Expense:						
	(1) Current Tax	333.00	278.08	121.72	611.08	322.14	743.67
	(2) Deferred Tax	(30.77)	59.59	(31.12)	28.82	(61.48)	(110.96)
IX.	<b>Profit / (Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>791.36</b>	<b>433.86</b>	<b>374.91</b>	<b>1,225.22</b>	<b>812.70</b>	<b>1,851.02</b>
X.	Profit / (Loss) from Discontinued Operations [Refer Note No.3 (a) below]	-	77,643.92	1,284.18	77,643.92	1,525.55	3,294.14
XI.	Tax Expense from Discontinued Operations [Refer Note No.3 (b) below]	(199.95)	17,991.69	378.28	17,791.74	457.86	986.33
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	199.95	59,652.23	905.90	59,852.18	1,067.69	2,307.81
XIII.	<b>Profit / (Loss) for the period (IX + XII)</b>	<b>991.31</b>	<b>60,086.09</b>	<b>1,280.81</b>	<b>61,077.40</b>	<b>1,880.39</b>	<b>4,158.83</b>
XIV.	<b>Other Comprehensive Income:</b>						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	235.04	(1.22)	(78.49)	233.82	305.90	213.31
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(26.89)	0.14	8.97	(26.75)	(34.16)	(25.82)
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	<b>Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period] including Human Pharma operations - Discontinued</b>	<b>1,199.46</b>	<b>60,085.01</b>	<b>1,211.29</b>	<b>61,284.47</b>	<b>2,152.13</b>	<b>4,346.32</b>
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)	-	-	-	-	-	31,108.67
XVI.	<b>Earnings per Equity Share (For Continuing Operations):</b>						
	(1) Basic (in Rs.)	5.60	3.07	2.65	8.67	5.75	13.10
	(2) Diluted (in Rs.)	5.60	3.07	2.65	8.67	5.75	13.10
XVII.	<b>Earnings per Equity Share (For Human Pharma operation-Discontinued):</b>						
	(1) Basic (in Rs.)	1.42	422.16	6.41	423.57	7.56	16.33
	(2) Diluted (in Rs.)	1.42	422.16	6.41	423.57	7.56	16.33
XVIII.	<b>Earnings per Equity Share (For Continuing and Human Pharma operations - Discontinued):</b>						
	(1) Basic (in Rs.)	7.02	425.23	9.06	432.24	13.31	29.43
	(2) Diluted (in Rs.)	7.02	425.23	9.06	432.24	13.31	29.43

**Notes:**

- (1) The above financial results for the Second Quarter and Half-year ended 30th September, 2022 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 27th October, 2022 and approved by the Board of Directors of the Company at its meeting held on 28th October, 2022 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) (a) Profit from Discontinued Operations:
  - (i) Gain on sale of Undertaking:

During the First Quarter, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the Division stands transferred as a going concern on slump sale basis for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s. BSV Pharma Private Ltd (BSV) with effect from 9th May, 2022.

The consideration for the transfer is 74% cash (Rs.59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provide for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its Nominees, after they obtain necessary regulatory clearances at the issue price.

The gain on sale of this Undertaking amounts to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which Company has incurred expenses amounting to Rs.57.28 lakhs till 30th September 2022).
  - (ii) Profit from Human Pharma Division Operations:

The total income of Human Pharma Division up to the date of sale i.e. 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which is no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs.1,214.47 lakhs.
- (b) Tax expense of Discontinued Operations:

The tax expense of Rs.17,487.80 lakhs on account of the transfer includes Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,831.00 lakhs net of Deferred Tax of Rs.343.20 lakhs.

The tax expense on the profit for the Half-Year from the operations of Human Pharma Division was Rs.303.94 lakhs, net of reversal of Rs.199.95 lakhs.
- (4) Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamil Nadu on which the Company had earned a profit of Rs.249.05 lakhs.
- (5) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) This Statement is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)), National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).

## (8) Statement of Assets and Liabilities as at 30th September, 2022:

(Rs. in lakhs)

Sl. No.	Particulars	As on	As on
		30/09/2022	31/03/2022
		Unaudited	Audited
(A)	<b>ASSETS:</b>		
I	<b>Non-Current Assets:</b>		
(a)	Property, Plant and Equipment	6,412.69	6,922.13
(b)	Right of Use Asset	1,098.23	1,096.49
(c)	Capital Work-in-Progress	59.06	18.67
(d)	Other Intangible Assets	5.55	8.63
(e)	Financial Assets		
(i)	Investments	1,747.28	1,513.47
(ii)	Others Financial Assets	231.37	231.37
(f)	Non-current Tax Assets (Net)	96.17	438.85
(g)	Deferred Tax Assets (Net)	732.93	730.28
(h)	Other Non-current Assets	61.65	43.85
	<b>Total Non-Current Assets</b>	<b>10,444.93</b>	<b>11,003.74</b>
II	<b>Current Assets:</b>		
(a)	Inventories	7,598.44	7,892.44
(b)	Financial Assets		
(i)	Investments	20,839.03	-
(ii)	Trade Receivables	7,697.75	5,358.02
(iii)	Cash and Cash Equivalents	15,384.96	1,486.42
(iv)	Bank balances other than (iii) above	58,973.00	25,864.34
(v)	Other Financial Assets	1,507.99	746.65
(c)	Other Current Assets	1,342.23	1,074.57
	<b>Total Current Assets</b>	<b>1,13,343.40</b>	<b>42,422.44</b>
	Human Pharma - Assets of discontinued business	-	2,428.66
	<b>TOTAL ASSETS</b>	<b>1,23,788.33</b>	<b>55,854.84</b>
(B)	<b>EQUITY AND LIABILITIES:</b>		
(1)	<b>Equity</b>		
(a)	Equity Share Capital	1,413.03	1,413.03
(b)	Other Equity	91,421.55	31,550.11
	<b>Equity attributable to owners of the Company</b>	<b>92,834.58</b>	<b>32,963.14</b>
	<b>Total Equity</b>	<b>92,834.58</b>	<b>32,963.14</b>
(2)	<b>Liabilities</b>		
	<b>Non-current Liabilities:</b>		
(a)	Financial Liabilities:		
(i)	Lease Liabilities	154.47	133.83
(b)	Provisions	663.39	515.65
(c)	Deferred Revenue Income	170.39	188.78
	<b>Total Non-current Liabilities</b>	<b>988.25</b>	<b>838.26</b>
	<b>Current Liabilities:</b>		
(a)	Financial Liabilities		
(i)	Borrowings	2,140.72	2,038.44
(ia)	Lease Liabilities	60.68	48.98
(ii)	Trade Payables:		
(A)	Total outstanding dues of Micro Enterprises and Small Enterprises	1,590.93	2,074.60
(B)	Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	10,715.41	8,271.12
(iii)	Other Financial Liabilities	4,033.36	6,111.40
(b)	Other Current Liabilities	496.11	618.88
(c)	Provisions	661.28	431.93
(d)	Current Tax Liabilities (Net)	10,267.01	309.43
	<b>Total Current Liabilities</b>	<b>29,965.50</b>	<b>19,904.78</b>
	Human Pharma - Liabilities of discontinued business	-	2,148.66
	<b>TOTAL LIABILITIES</b>	<b>30,953.75</b>	<b>22,891.70</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,23,788.33</b>	<b>55,854.84</b>



## (9) Statement of Cash Flow for the Half-year ended 30th September, 2022:

(Rs. in lakhs)

Particulars	For the Half-	For the Half-	For the year
	year ended	year ended	ended
	(30/09/2022)	(30/09/2021)	(31/03/2022)
	Unaudited	Unaudited	Audited
<b>Cash Flow from Operating activities:</b>			
<b>Profit Before tax from Continuing operations</b>	<b>1,865.12</b>	<b>1073.36</b>	<b>2,483.73</b>
<b>Profit Before tax from Human Pharma operations</b>	<b>77,643.92</b>	<b>1525.55</b>	<b>3,294.14</b>
<b>Profit before tax for Continuing operations and Human Pharma operations</b>	<b>79,509.04</b>	<b>2598.91</b>	<b>5,777.87</b>
<b>Adjustments for:</b>			
Remeasurements of defined benefit plans	-	-	16.45
Depreciation and amortisation Expenses	662.98	660.64	1,318.98
Provision for Doubtful Debts	(4.04)	28.14	32.02
Bad debts written off	3.43	-	18.39
Creditors written back	-	-	(25.35)
Interest paid	358.19	117.95	396.24
Interest received	(1,957.71)	(645.82)	(1,472.07)
(Profit) / Loss on Sale of Assets / Impairment	(0.51)	(249.12)	(249.10)
Dividend income	(6.33)	(5.36)	(9.80)
Un Realised Forex (Gain) / Loss	(18.04)	-	-
Gain from Sale of Human Pharma Division (Net of Expenses)	(76,429.45)	-	-
<b>Operating Profit before working Capital Changes:</b>	<b>2,117.56</b>	<b>2,505.34</b>	<b>5,803.63</b>
<b>Adjustments for Working Capital changes:</b>			
Inventories	1,044.02	(202.17)	(1,612.07)
Trade receivables	(660.22)	(1,290.03)	(960.38)
Other Receivables	(112.96)	44.32	(160.33)
Trade payables	(164.31)	2613.03	1,292.92
Other liabilities	(3,254.72)	513.06	1,046.08
Deferred Revenue Income	(18.39)	26.41	8.07
<b>Cash generated from operations:</b>	<b>(1,049.02)</b>	<b>4,209.96</b>	<b>5,417.92</b>
<b>Less: Direct Taxes Paid</b>	<b>434.67</b>	<b>618.04</b>	<b>1,622.61</b>
<b>Add: Direct Taxes Received</b>	<b>349.88</b>	<b>167.72</b>	<b>704.32</b>
<b>Net Cash generated from (used in) Operating Activities</b>	<b>(1,133.81)</b>	<b>3,759.64</b>	<b>4,499.63</b>
<b>Cash Flow from Investing Activities:</b>			
Purchase of Fixed Assets / Capital advances	(225.03)	(312.56)	(649.47)
Sale of Fixed Assets	6.48	254.91	258.16
Sale Proceeds of Human Pharma Undertaking (Net of Expenses)	56,901.62	-	-
Direct Tax on sale of Human Pharma Undertaking	(8,076.00)	-	-
Investments in Bank deposits (Net)	(33,108.66)	(1,759.04)	(4,050.69)
Interest received	1,190.67	565.48	1,377.47
Dividend Received	6.33	5.36	9.80
<b>Net Cash generated from (used in) investing Activities</b>	<b>16,695.41</b>	<b>(1,245.85)</b>	<b>(3,054.73)</b>
<b>Cash Flow from Financing Activities:</b>			
Borrowings (Net of repayment)	111.39	(1,284.27)	330.10
Interest Paid on other than Lease Activity	(337.70)	(104.73)	(367.77)
Interest Paid on Lease Activity	(15.49)	(13.22)	(28.47)
Dividend Paid (Including transfer to Investors Protection Fund account)	(1,421.26)	(847.82)	(847.82)
<b>Net Cash generated from (used in) Financing Activities</b>	<b>(1,663.06)</b>	<b>(2,250.04)</b>	<b>(913.96)</b>
Net Increase / (Decrease) in Cash and Cash Equivalents	13,898.54	263.75	530.94
Cash and Cash Equivalents as at the beginning of the year	1,486.42	955.48	955.48
<b>Total</b>	<b>15,384.96</b>	<b>1,219.23</b>	<b>1,486.42</b>
<b>Cash and Cash Equivalents as at the end of the year (as per Balance Sheet)</b>	<b>15,384.96</b>	<b>1,219.23</b>	<b>1,486.42</b>

For TTK HEALTHCARE LIMITED


  
T T RAGHUNATHAN  
Executive Chairman

Place : Chennai  
Date : October 28, 2022



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

**SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2022**

							(Rs. in lakhs)
Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2022)	(30/06/2022)	(30/09/2021)	(30/09/2022)	(30/09/2021)	(31/03/2022)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	<b>Segment Revenue:</b> <b>(Sales and Other Operating Income)</b>						
	(a) Animal Welfare Division	2,713.05	2,483.48	2,541.08	5,196.53	4,770.38	9,910.79
	(b) Consumer Products	5,660.00	7,585.31	5,444.84	13,245.31	11,170.53	21,743.70
	(c) Medical Devices	1,612.28	1,932.85	1,405.27	3,545.13	1,978.61	5,091.90
	(d) Protective Devices	4,268.47	4,522.15	3,216.81	8,790.62	5,767.59	13,326.15
	(e) Foods	2,714.88	2,725.93	2,434.33	5,440.81	4,489.25	9,803.44
	(f) Others	10.50	12.31	5.60	22.81	8.13	48.01
	(g) Human Pharma-Discontinued operations	-	1,107.20	5,587.62	1,107.20	9,530.18	19,804.34
	<b>Total</b>	<b>16,979.18</b>	<b>20,369.23</b>	<b>20,635.55</b>	<b>37,348.41</b>	<b>37,714.67</b>	<b>79,728.33</b>
	Less : Inter Segment Revenue	-	-	-	-	-	-
	<b>Net Sales / Income from Operations</b>	<b>16,979.18</b>	<b>20,369.23</b>	<b>20,635.55</b>	<b>37,348.41</b>	<b>37,714.67</b>	<b>79,728.33</b>
2.	<b>Segment Results:</b> <b>[Profit (+) / Loss (-) before tax and interest from each segment]</b>						
	(a) Animal Welfare Division	172.57	85.31	282.87	257.88	538.46	928.71
	(b) Consumer Products	565.70	649.48	318.06	1,215.18	1,033.42	2,323.23
	(c) Medical Devices	239.35	300.45	205.63	539.80	59.69	319.68
	(d) Protective Devices	76.28	105.13	(474.04)	181.41	(470.80)	(536.22)
	(e) Foods	(146.51)	(136.36)	(56.66)	(282.87)	(169.34)	(244.69)
	(f) Others	8.05	7.19	4.99	15.24	7.88	33.00
	(g) Human Pharma-Discontinued operations [Refer Note No.4 (a) below]	-	77,651.59	1,439.14	77,651.59	1,849.32	4,001.61
	<b>Total</b>	<b>915.44</b>	<b>78,662.79</b>	<b>1,719.99</b>	<b>79,578.23</b>	<b>2,848.63</b>	<b>6,825.32</b>
	Less : Finance Cost	79.61	278.58	55.43	358.19	117.95	396.24
	Less : Unallocable Expenses (Net of Unallocable Income)	(257.76)	(31.24)	(85.13)	(289.00)	131.77	651.21
	<b>Total Profit (+) / Loss (-) before tax</b>	<b>1,093.59</b>	<b>78,415.45</b>	<b>1,749.69</b>	<b>79,509.04</b>	<b>2,598.91</b>	<b>5,777.87</b>
		<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>
		<b>30/09/2022</b>	<b>30/06/2022</b>	<b>30/09/2021</b>	<b>30/09/2022</b>	<b>30/09/2021</b>	<b>31/03/2022</b>
3.	<b>Segment Assets:</b>						
	(a) Animal Welfare Division	4,110.97	4,066.94	6,893.59	4,110.97	6,893.59	4,044.75
	(b) Consumer Products	3,716.25	3,941.38	2,634.51	3,716.25	2,634.51	4,017.12
	(c) Medical Devices	5,430.18	4,951.83	4,172.72	5,430.18	4,172.72	4,382.64
	(d) Protective Devices	9,697.63	9,376.44	7,953.90	9,697.63	7,953.90	8,449.60
	(e) Foods	8,688.59	9,763.06	9,515.96	8,688.59	9,515.96	9,610.29
	(f) Others	219.03	217.35	179.49	219.03	179.49	208.32
	(g) Human Pharma - Assets of discontinued business	-	-	-	-	-	2,428.66
	<b>Total</b>	<b>31,862.65</b>	<b>32,317.00</b>	<b>31,350.17</b>	<b>31,862.65</b>	<b>31,350.17</b>	<b>33,141.38</b>
	Unallocated [Refer Note No.4 (b) below]	91,925.68	1,06,700.83	26,485.50	91,925.68	26,485.50	28,327.64
	<b>Total Assets</b>	<b>1,23,788.33</b>	<b>1,39,017.83</b>	<b>57,835.67</b>	<b>1,23,788.33</b>	<b>57,835.67</b>	<b>61,469.02</b>
4.	<b>Segment Liabilities:</b>						
	(a) Animal Welfare Division	4,925.40	4,547.94	7,501.43	4,925.40	7,501.43	5,311.75
	(b) Consumer Products	6,041.62	6,972.27	7,436.43	6,041.62	7,436.43	6,419.38
	(c) Medical Devices	2,057.54	1,968.55	1,664.73	2,057.54	1,664.73	1,527.73
	(d) Protective Devices	3,719.57	3,632.51	3,166.93	3,719.57	3,166.93	3,389.08
	(e) Foods	1,627.22	1,641.96	1,631.57	1,627.22	1,631.57	1,556.44
	(f) Others	133.47	137.91	131.92	133.47	131.92	141.37
	(g) Human Pharma - Liabilities of discontinued business	-	-	-	-	-	2,148.66
	<b>Total</b>	<b>18,504.82</b>	<b>18,901.14</b>	<b>21,533.01</b>	<b>18,504.82</b>	<b>21,533.01</b>	<b>20,494.41</b>
	Unallocated	12,448.93	27,068.54	5,533.72	12,448.93	5,533.72	8,011.47
	<b>Total Liabilities</b>	<b>30,953.75</b>	<b>45,969.68</b>	<b>27,066.73</b>	<b>30,953.75</b>	<b>27,066.73</b>	<b>28,505.88</b>

**Notes:**

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
  - ❖ Animal Welfare (earlier included in Pharmaceuticals Segment) include products for Veterinary use.
  - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
  - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
  - ❖ Foods comprise manufacturing and marketing of Food Products.
  - ❖ "Others" include Printing and Publishing of Maps and Atlases.
  - ❖ Human Pharma (earlier included in Pharmaceuticals Segment) include products for Human use
3. Segment Assets and Segment Liabilities shown under Animal Welfare Division as at 30th September, 2021 include that of Human Pharma Division also.
4. (a) Segment Results of Human Pharma Division include gain on sale of the division amounting to Rs.76,429.45 lakhs.  
(b) Unallocated Segment Assets include consideration on sale of Human Pharma Division received in the form of cash and equity.
5. The Segmentwise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment. The unallocable assets and liabilities includes those which are not identifiable to any specific segment.
6. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



Place : Chennai  
Date : October 28, 2022

T T RAGHUNATHAN  
Executive Chairman



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

**EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2022**

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		(Rs. in lakhs)
		(30/09/2022)	(30/06/2022)	(30/09/2021)	(30/09/2022)	(30/09/2021)	For the Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	(31/03/2022)
1.	Total income from Operations	16,979.18	20,369.23	20,635.55	37,348.41	37,714.67	79,728.33
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	1,093.59	78,415.45	1,500.64	79,509.04	2,349.86	5,528.82
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,093.59	78,415.45	1,749.69	79,509.04	2,598.91	5,777.87
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	991.31	60,086.09	1,280.81	61,077.40	1,880.39	4,158.83
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,199.46	60,085.01	1,211.29	61,284.47	2,152.13	4,346.32
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	31,108.67
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	(a) Basic (in Rs.)	7.02	425.23	9.06	432.24	13.31	29.43
	(b) Diluted (in Rs.)	7.02	425.23	9.06	432.24	13.31	29.43

**Notes:**

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the Second Quarter and Half-year ended 30th September, 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Second Quarter ended 30th September, 2022 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) These financial results have been reviewed by the Audit Committee at its meeting held on 27th October 2022 and approved by the Board of Directors of the Company at its meeting held on 28th October 2022 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (4) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (5) (a) Profit from Discontinued Operations:
- (i) Gain on sale of Undertaking:
- During the First Quarter, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the Division stands transferred as a going concern on slump sale basis for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s. BSV Pharma Private Ltd (BSV) with effect from 9th May, 2022.
- The consideration for the transfer is 74% cash (Rs.59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provide for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its Nominees, after they obtain necessary regulatory clearances at the issue price.
- The gain on sale of this Undertaking amounts to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which Company has incurred expenses amounting to Rs.57.28 lakhs till 30th September 2022).
- (ii) Profit from Human Pharma Division Operations:
- The total income of Human Pharma Division up to the date of sale i.e. 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which is no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs. 1,214.47 lakhs.
- (b) Tax expense of Discontinued Operations:
- The tax expense of Rs.17,487.80 lakhs on account of the transfer includes Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,831.00 lakhs net of Deferred Tax of Rs.343.20 lakhs.
- The tax expense on the profit for the Half-Year from the operations of Human Pharma Division was Rs.303.94 lakhs, net of reversal of Rs.199.95 lakhs.
- (6) Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamil Nadu on which the Company had earned a profit of Rs.249.05 lakhs.
- (7) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (8) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place : Chennai  
Date : October 28, 2022T T RAGHUNATHAN  
Executive Chairman

# PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

## Independent Auditor's Review Report on review of Interim Financial Results

### To the Board of Directors of TTK Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of **TTK Healthcare Limited** (the "Company"), for the quarter and half year ended 30<sup>th</sup> September 2022 ("the Statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") which has been initialed by us for identification.

### Management's Responsibility

2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

### Auditor's Responsibility

3. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

### Conclusion

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Obligations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018

  
**S. Rajeshwari**

Partner

Membership No. 024105



Place: Chennai

Date: 28<sup>th</sup> October 2022

UDIN: 22024105BBBVR1576